Skip to content
Peptigraph home

TRIUMPH-1: Retatrutide Phase 3 trial (NCT05929066)

A Master Protocol to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (TRIUMPH-1)

Registry record checked

At a glance

Phase
Phase 3
Status
Completed
Enrolment
2,335
actual
Start
10 Jul 2023 (actual)
Primary completion
6 Apr 2026 (actual)
Sponsor
Eli Lilly and Company
Design

Arms and doses

NCT05929066 study arms
ArmTypeInterventionsDescription
Retatrutide Dose 1ExperimentalDrug: RetatrutideParticipants will receive retatrutide subcutaneously (SC).
Retatrutide Dose 2ExperimentalDrug: RetatrutideParticipants will receive retatrutide SC.
Retatrutide Dose 3ExperimentalDrug: RetatrutideParticipants will receive retatrutide SC.
PlaceboPlacebo comparatorDrug: PlaceboParticipants will receive placebo.
Retatrutide Extension PeriodExperimentalDrug: RetatrutideParticipants will receive retatrutide after the placebo-controlled 80 week treatment period for an additional 24 weeks.
Endpoints

Primary endpoint

NCT05929066 primary outcomes
MeasureTime frame
Percent Change From Baseline in Body WeightBaseline, Week 80
Change from Baseline in Apnea-Hypopnea Index (AHI) Events Per Hour for GSA1 SubsetBaseline, Week 80
Change from Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score for GOA1 SubsetBaseline, Week 80
Percent Change from Baseline in Body Weight in Participants in Extension SubsetBaseline, Week 104
Endpoints

Key secondary endpoints

The first secondary outcomes listed on the registry record.

NCT05929066 secondary outcomes
MeasureTime frame
Percent Change from Baseline in Body Weight in Participants with Baseline BMI ≥ 35 kg/m2Baseline, Week 80
Percentage of Participants who Achieve Body Weight Reduction of ≥ 5%Baseline through Week 80
Percentage of Participants who Achieve Body Weight Reduction of ≥ 10%Baseline through Week 80
Percentage of Participants who Achieve Body Weight Reduction of ≥ 15%Baseline through Week 80
Percentage of Participants who Achieve Body Weight Reduction of ≥ 20%Baseline through Week 80
Percentage of Participants who Achieve Body Weight Reduction of ≥ 25%Baseline through Week 80
Percentage of Participants who Achieve Body Weight Reduction of ≥ 30%Baseline through Week 80
Percentage of Participants who Achieve Body Weight Reduction of ≥ 35%Baseline through Week 80
Change from Baseline in Waist CircumferenceBaseline, Week 80
Change from Baseline in Systolic Blood Pressure (SBP)Baseline, Week 80
Percent Change from Baseline in TriglyceridesBaseline, Week 80
Percent Change from Baseline in Non-High-Density Lipoprotein (HDL)-CholesterolBaseline, Week 80
Eligibility

Who could enrol

Sex
All
Minimum age
18 Years
Maximum age
Not stated
Results

Results

No results posted on ClinicalTrials.gov as of 2 Oct 2026.

TRIUMPH-1 as published for retatrutide in adults with obesity

Adults with obesity but not diabetes were assigned weekly retatrutide at 4, 9 or 12 mg, or placebo, for 80 weeks.[2]

Mean percent change in body weight was -17.6% (4 mg), -23.7% (9 mg) and -25.0% (12 mg) against -3.9% on placebo.[2]

In participants with knee osteoarthritis, WOMAC pain scores changed by -3.2, -3.5 and -3.6 against -1.9 on placebo for the hybrid estimand.[2]

Primary outcomes also covered the apnea-hypopnea index in the 243 participants with obstructive sleep apnea.[2]

Sources

  1. 1A Master Protocol to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (TRIUMPH-1)ClinicalTrials.gov (U.S. National Library of Medicine) · registry recordclinicaltrials.govAccessed 2 Oct 2026
  2. 2Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity.The New England journal of medicine · 2026PMID 42814954Accessed 2 Oct 2026

Found an error? Report a correction.